European Drug Developers Reassess Manufacturing Partnerships as Generic and Biopharmaceutical Pipelines Grow More Complex

Finding manufacturing support has become a more involved decision for pharmaceutical companies developing both generic medicines and biopharmaceutical products. What once centred on securing production capacity now extends much further. Companies are weighing whether a development partner can support a product from early process work through commercial manufacturing without creating unnecessary delays between stages.

That shift is changing how development services are evaluated across Europe. Contract development and manufacturing organisations are no longer viewed simply as production facilities. Their involvement often begins while manufacturing processes are still being refined, allowing developers to identify technical issues before products move into larger production campaigns.

The change shows that there are kinds of medicines being developed. Generic medicines still need ways to be made and reliable production, but biopharmaceutical products are different. These products have complicated technology. Biological materials act differently during production than small-molecule medicines. This makes sure that the process is consistent, from the start, not something considered at the end.

Drug developers increasingly want development partners that understand these differences from the outset. Process design, analytical methods and manufacturing documentation often evolve together, particularly for biologic products. Separating those activities across several organisations can introduce additional coordination work and increase the likelihood of delays during technology transfer.

European development providers have gradually expanded their role to address these expectations. Instead of limiting their work to manufacturing, many now support process development before production begins. That allows pharmaceutical companies to refine manufacturing methods while preparing for later clinical or commercial requirements, rather than revisiting technical questions after production has already started.

Medicine makers also gain from this approach, although the things that are important to them are often different. The time it takes to make a new medicine is often decided by how fast others are making the same thing, and when the medicine will be available to buy. If the people who make the medicine can work with the people who plan the production, they can help stop things from going wrong when they are switching from one part of the project to another, even when the medicine is made with ingredients that have been used before in other medicines.

The conversation has become less about finding available manufacturing space and more about finding technical continuity. Pharmaceutical companies increasingly recognize that changes between development teams, manufacturing sites or production methods can affect schedules long after initial planning has been completed. Reducing those handoffs has become part of the evaluation process.

In Europe, pharmaceutical companies usually make products for different markets. So the companies that help with manufacturing have to follow a lot of rules when they make these products. They also have to keep track of everything they do when they are making these products. When pharmaceutical companies are choosing a partner to work with, they think about whether this partner can help with the science part of making a product and the manufacturing part. Pharmaceutical companies need a partner that can do both of these things well.

The European CDMO sector is getting bigger. This is what a lot of people are expecting. Building facilities is important, but it is not the only thing that will help. The European CDMO sector needs people who are good at science and technology to help with making more of something, to help with analysing things and to keep track of what is happening when the European CDMO sector is working on new projects. The European CDMO sector is looking for these kinds of people because it wants to make sure that everything goes smoothly.

That combination of scientific support and manufacturing capability is becoming a defining feature of development partnerships. Pharmaceutical companies are looking for relationships that continue beyond a single production campaign and remain effective as products move through different stages of development.

The balance between generic medicines and advanced biopharmaceutical products will continue to shape demand for European development services. Manufacturing capacity is still part of the equation, but many developers are placing equal weight on technical collaboration and the ability to carry knowledge forward throughout the product lifecycle.